

Alfredo Carrato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1316796/alfredo-carrato-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

341 papers	12,245 citations	55 h-index	101 g-index
392 ext. papers	14,099 ext. citations	5.3 avg, IF	5.44 L-index

#	Paper	IF	Citations
341	Precision Medicine: Genotyping to Better Manage Irinotecan-Induced Toxicity.. <i>JCO Oncology Practice</i> , 2022 , OP2100858	2.3	0
340	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 774170	5.6	0
339	Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from blood samples: Results of a multiplex biomarker signature validation study.. <i>Clinical and Translational Gastroenterology</i> , 2022 , 13,	4.2	3
338	A faecal microbiota signature with high specificity for pancreatic cancer.. <i>Gut</i> , 2022 ,	19.2	5
337	Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.. <i>European Journal of Cancer</i> , 2022 , 166, 229-239	7.5	0
336	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies.. <i>Environmental Health Perspectives</i> , 2022 , 130, 57006	8.4	1
335	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. <i>Gut</i> , 2021 , 70, 319-329	19.2	16
334	Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.. <i>EBioMedicine</i> , 2021 , 75, 103797	8.8	4
333	Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. <i>Cancers</i> , 2021 , 13,	6.6	2
332	Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). <i>European Journal of Surgical Oncology</i> , 2021 ,	3.6	1
331	Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. <i>Gastroenterology</i> , 2021 ,	13.3	5
330	Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals Negativity and a Longer Overall Survival. <i>Cancers</i> , 2021 , 13,	6.6	1
329	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021 , 23, 988-1000	3.6	7
328	Chemotherapy for Nonresectable Pancreatic Cancer 2021 , 530-537		
327	Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. <i>Molecular Cancer</i> , 2021 , 20, 73	42.1	3
326	Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. <i>Cancers</i> , 2021 , 13,	6.6	3
325	Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. <i>Future Oncology</i> , 2021 , 17, 1843-1854	3.6	2

324	The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211043341	3.2	0
323	First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. <i>Drugs and Aging</i> , 2021 , 38, 219-231	4.7	2
322	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. <i>Genome Medicine</i> , 2021 , 13, 15	14.4	6
321	Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. <i>Clinical and Translational Oncology</i> , 2021 , 1	3.6	1
320	Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium. <i>Gastroenterology</i> , 2021 , 161, 1751-1757	13.3	2
319	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. <i>JCO Oncology Practice</i> , 2021 , 17, e1162-e1169	2.3	
318	Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. <i>European Journal of Cancer Prevention</i> , 2021 , 30, 423-430	2	
317	Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021 , 148, 2048-2058	7.5	4
316	ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. <i>Nature Communications</i> , 2020 , 11, 2682	17.4	25
315	BRAF Mutated Colorectal Cancer: New Treatment Approaches. <i>Cancers</i> , 2020 , 12,	6.6	9
314	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 165-177	3.8	6
313	Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
312	Ramucirumab treatment in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2020 , 9, 83	2.3	
311	Treatment patterns for metastatic colorectal cancer in Spain. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1455-1462	3.6	3
310	A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. <i>EBioMedicine</i> , 2020 , 53, 102675	8.8	16
309	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. <i>ESMO Open</i> , 2020 , 5,	6	20
308	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1009-1018	4	15
307	First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4017-4017	2.2	2

306	Evaluation of Spanish hospitals participating in the Quality Oncology Practice Initiative program.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 222-222	2.2	
305	Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation. <i>Oncotarget</i> , 2020 , 11, 2137-2140	3.3	0
304	Survey of treatment recommendations for elderly patients with glioblastoma. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1329-1334	3.6	2
303	Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. <i>Environment International</i> , 2020 , 135, 105346	12.9	8
302	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020 , 69, 7-17	19.2	159
301	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , 2020 , 25, e1-e4	5.7	5
300	Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
299	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
298	Bratislava Statement: consensus recommendations for improving pancreatic cancer care. <i>ESMO Open</i> , 2020 , 5, e001051	6	2
297	A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. <i>ESMO Open</i> , 2020 , 5, e000850	6	50
296	Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. <i>European Journal of Cancer</i> , 2020 , 139, 51-58	7.5	1
295	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020 , 25, e1428-e1432	5.7	2
294	Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. <i>Journal of Pain Research</i> , 2019 , 12, 2349-2358	2.9	2
293	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , 2019 , 30, 439-446	10.3	14
292	Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers. <i>United European Gastroenterology Journal</i> , 2019 , 7, 682-688	5.3	0
291	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019 , 66, 1-8	3.9	14
290	First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). <i>BMC Cancer</i> , 2019 , 19, 533	4.8	9
289	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e287-e293	3.8	9

288	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, 305-312.e3	4.9	3
287	Screening of Individuals at High Risk for Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1916-1917	6.9	
286	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys". <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	27
285	Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs. <i>Cancers</i> , 2019 , 11,	6.6	18
284	Tumor-associated macrophage-secreted 14-3-3 signals via AXL to promote pancreatic cancer chemoresistance. <i>Oncogene</i> , 2019 , 38, 5469-5485	9.2	31
283	Management and supportive treatment of frail patients with metastatic pancreatic cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 398-404	3.6	5
282	Author's reply to: Air pollution and incident bladder cancer: A risk assessment. <i>International Journal of Cancer</i> , 2019 , 145, 3178	7.5	
281	CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. <i>Bladder Cancer</i> , 2019 , 5, 159-169	1	2
280	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2019 , 121, 378-383	8.7	2
279	Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8
278	Tumour location and efficacy of first-line EGFR inhibitors in wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. <i>ESMO Open</i> , 2019 , 4, e000599	6	7
277	Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 637-637	2.2	
276	QIM19-125: Nonclinical Needs of Cancer Patients in Spain Under Different Perspectives: A Comparative Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, QIM19-125	7.3	
275	Implementation of the Quality Training Program in Spain.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18296-e18296	2.2	
274	Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18266-e18266	2.2	1
273	Non-clinical needs of cancer patients in Spain under different perspectives: A comparative study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18266-e18266	2.2	
272	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15707-e15707	2.2	
271	The Quality Oncology Practice Initiative Program: Experience in Spain.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18267-e18267	2.2	

270	Circulating endothelial cells: Prognostic value in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13517-e13517	2.2	
269	Strategies for reducing grade 2 and 3 adverse events due to immunotherapy in a Spanish university hospital.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18295-e18295	2.2	
268	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. <i>International Journal of Cancer</i> , 2019 , 144, 1540-1549	7.5	4
267	Ambient air pollution and incident bladder cancer risk: Updated analysis of the Spanish Bladder Cancer Study. <i>International Journal of Cancer</i> , 2019 , 145, 894-900	7.5	14
266	Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. <i>Gut</i> , 2019 , 68, 130-139	19.2	86
265	A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e323-e329	3.8	11
264	Management of hyperbilirubinaemia in pancreatic cancer patients. <i>European Journal of Cancer</i> , 2018 , 94, 26-36	7.5	3
263	Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. <i>International Journal of Epidemiology</i> , 2018 , 47, 473-483	7.8	20
262	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. <i>Annals of Oncology</i> , 2018 , 29, 439-444	10.3	10
261	Asthma status is associated with decreased risk of aggressive urothelial bladder cancer. <i>International Journal of Cancer</i> , 2018 , 142, 470-476	7.5	8
260	Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer. <i>Molecular Cancer</i> , 2018 , 17, 114	42.1	45
259	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. <i>Journal of Cancer</i> , 2018 , 9, 1978-1988	4.5	14
258	Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant colon cancer: Experience in Ramon y Cajal University Hospital.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 815-815	2.2	
257	Prognostic relevance of primary tumor location in stage III and II colon cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 703-703	2.2	
256	Benefit of adjuvant treatment in stages II and III colon cancer: Experience at the Ramon y Cajal University Hospital.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 842-842	2.2	
255	Impact of adjuvant chemotherapy treatment according to tumor primary location in colorectal cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 655-655	2.2	
254	Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22175-e22175	2.2	
253	The future of precision medicine, strengths and weaknesses: An expert position paper.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18879-e18879	2.2	

252	Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15505-e15505 ^{2,2}		
251	Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18785-e18785	2.2	
250	The Quality Oncology Practice Initiative program: Experience in Spain.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 310-310	2.2	
249	Strategies for reducing grade 2 and 3 adverse events due to immunotherapy in a Spanish university hospital.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 288-288	2.2	
248	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <i>Targeted Oncology</i> , 2018 , 13, 69-78	5	
247	Efficacy of adjuvant chemotherapy for elderly patients with colon cancer. <i>Annals of Oncology</i> , 2018 , 29, v65	10.3	2
246	Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. <i>Oncotarget</i> , 2018 , 9, 32984-32996	3.3	20
245	Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1. <i>Oncogenesis</i> , 2018 , 7, 76	6.6	13
244	A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds. <i>Micromachines</i> , 2018 , 9,	3.3	12
243	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. <i>Gut</i> , 2017 , 66, 314-322	19.2	37
242	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 446-464	2.2	176
241	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. <i>Scientific Reports</i> , 2017 , 7, 41371	4.9	2
240	Diagnosis and staging of pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1205-1216	3.6	8
239	Supportive care in pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1293-1302	3.6	16
238	Biomarkers in pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1430-1437	3.6	7
237	First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). <i>European Journal of Cancer</i> , 2017 , 81, 191-202	7.5	52
236	Optimization of Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1999-2007	6.1	8
235	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. <i>Annals of Oncology</i> , 2017 , 28, 1618-1624	10.3	15

234	European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish. <i>Clinical and Translational Oncology</i> , 2017 , 19, 288-290	3.6	
233	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2017 , 19, 667-681	3.6	18
232	Surgery for pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1303-1311	3.6	6
231	F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 1432-1441	12.9	25
230	Clinical behavior of solitary fibrous tumor: a retrospective review of 30 patients. <i>Clinical and Translational Oncology</i> , 2017 , 19, 357-363	3.6	8
229	Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15019-e15019	2.2	6
228	The Quality Oncology Practice Initiative program: Experience in Spain.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 214-214	2.2	1
227	Identification of quality care indicators in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 213-213.	2.2	2
226	Study on compliance with breakthrough cancer pain guidelines by medical oncologists in Spain.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18260-e18260	2.2	
225	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 1345-1363	5	64
224	Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature. <i>Medicine (United States)</i> , 2016 , 95, e4207	1.8	13
223	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016 , 25, 1203-14	5.6	20
222	Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3527-3527	2.2	3
221	Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3530-3530	2.2	1
220	A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 341-341	2.2	8
219	Circulating biomarkers exploratory study in loco-regional gastroesophageal adenocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 17-17	2.2	
218	Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3559-3559	2.2	
217	Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. <i>BMC Cancer</i> , 2016 , 16, 351	4.8	7

216	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 553-8	7.3	6
215	Refinement of screening for familial pancreatic cancer. <i>Gut</i> , 2016 , 65, 1314-21	19.2	54
214	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>American Journal of Clinical Pathology</i> , 2016 , 146, 647-669	1.9	30
213	Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1144-50	4	7
212	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2010-9	2.2	192
211	Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. <i>Cancer Treatment Reviews</i> , 2016 , 50, 142-147	14.4	17
210	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. <i>Annals of Oncology</i> , 2015 , 26, 921-927	10.3	110
209	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 109-17	1.6	14
208	Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 579-89	2.2	9
207	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). <i>Annals of Oncology</i> , 2015 , 26, 1987-1993	10.3	85
206	Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	23
205	PanGen-Fam: Spanish registry of hereditary pancreatic cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1911-7	7.5	32
204	A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2015 , 26, 2085-91	10.3	34
203	Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. <i>Molecular Diagnosis and Therapy</i> , 2015 , 19, 397-408	4.5	21
202	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. <i>BMC Genomics</i> , 2015 , 16, 403	4.5	59
201	Seom guidelines for the treatment of gastric cancer 2015. <i>Clinical and Translational Oncology</i> , 2015 , 17, 996-1004	3.6	18
200	Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. <i>BMC Cancer</i> , 2015 , 15, 797	4.8	116
199	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv279	9.7	107

198	Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer. <i>PLoS Genetics</i> , 2015 , 11, e1005689	6	49
197	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 201-11	1.6	143
196	Biomarkers for early diagnosis of pancreatic cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 305-15	4.2	29
195	A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4118-4118	2.2	8
194	ROLE OF PARENTERAL NUTRITION IN ONCOLOGIC PATIENTS WITH INTESTINAL OCCLUSION AND PERITONEAL CARCINOMATOSIS. <i>Nutricion Hospitalaria</i> , 2015 , 32, 1222-7	1	17
193	Prognostic factors in advanced gastric cancer after second-line treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 201-201	2.2	
192	Genetic and phenotypic characterization of families with familial pancreatic cancer and screening of high-risk individuals.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 242-242	2.2	
191	Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15061-e15061 ²		
190	Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14613-e14613	2.2	
189	Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14581-e14581	2.2	1
188	KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15252-e15252	2.2	
187	Kaposi sarcoma: A retrospective review.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e21520-e21520	2.2	
186	Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014 , 23, 1387-98	5.6	101
185	The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. <i>Cancer Research</i> , 2014 , 74, 5808-18	10.1	19
184	Whole genome prediction of bladder cancer risk with the Bayesian LASSO. <i>Genetic Epidemiology</i> , 2014 , 38, 467-76	2.6	10
183	Oncological translational research in the Spanish national health system: the INTRO study. <i>Clinical and Translational Oncology</i> , 2014 , 16, 686-95	3.6	
182	LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk. <i>British Journal of Cancer</i> , 2014 , 110, 2123-30	8.7	16
181	Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. <i>Clinical and Translational Oncology</i> , 2014 , 16, 914-20	3.6	5

180	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2014 , 16, 865-78	3.6	5
179	Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study. <i>Current Medical Research and Opinion</i> , 2014 , 30, 463-70	2.5	5
178	Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis. <i>PLoS ONE</i> , 2014 , 9, e89952	3.7	13
177	Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. <i>Current Medical Research and Opinion</i> , 2014 , 30, 447-61	2.5	29
176	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
175	LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk. <i>Epigenetics</i> , 2014 , 9, 1532-9	5.7	21
174	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 83-106	7	29
173	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. <i>European Urology</i> , 2014 , 65, 360-6	10.2	166
172	Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3560-3560	2.2	8
171	Prognostic value of stem cell quantification in stage II colon cancer. <i>PLoS ONE</i> , 2014 , 9, e88480	3.7	10
170	Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3651-TPS3651	2.2	
169	Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15253-e15253	2.2	
168	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15019-e15019	2.2	
167	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. <i>European Journal of Cancer</i> , 2013 , 49, 3616-24	7.5	63
166	Biological and statistical approaches for modeling exposure to specific trihalomethanes and bladder cancer risk. <i>American Journal of Epidemiology</i> , 2013 , 178, 652-60	3.8	16
165	Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. <i>Cancer Research</i> , 2013 , 73, 2211-20	10.1	82
164	Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. <i>Nature Genetics</i> , 2013 , 45, 1464-9	36.3	186
163	A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study. <i>European Journal of Cancer</i> , 2013 , 49, 1868-75	7.5	12

162	Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA. <i>Environmental Health Perspectives</i> , 2013 , 121, 650-6	8.4	66
161	Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2013 , 15, 705-11	3.6	7
160	Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1341-7	2.2	110
159	Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. <i>International Journal of Cancer</i> , 2013 , 133, 597-603	7.5	18
158	Journal Watch: Our expert panel highlights the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2013 , 2, 391-393	0.8	
157	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2013 , 2, 109-111	0.8	
156	Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. <i>PLoS ONE</i> , 2013 , 8, e83745	3.7	12
155	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. <i>Journal of Research in Medical Sciences</i> , 2013 , 18, 623-5	1.6	16
154	Imaging techniques in pancreatic cancer screening: Preliminary results from the PanGen-FAM registry.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1529-1529	2.2	
153	Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1359-67	3.5	6
152	Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 200-6	3.8	14
151	New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 457-67	3.5	6
150	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2012 , 23, 119-127	10.3	20
149	Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. <i>Human Molecular Genetics</i> , 2012 , 21, 1918-30	5.6	58
148	Pancreatic cancer risk and levels of trace elements. <i>Gut</i> , 2012 , 61, 1583-8	19.2	68
147	Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 4974-9	11.5	69
146	Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1897-904	9.7	28
145	A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4135-TPS4135	2.2	1

144	Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. <i>PLoS ONE</i> , 2012 , 7, e29396	3.7	33
143	Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. <i>PLoS ONE</i> , 2012 , 7, e45025	3.7	20
142	Chemotherapy-induced changes in the physiologic reserve of elderly patients diagnosed with cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e19590-e19590	2.2	
141	Spanish national hereditary pancreatic cancer registry (PanFAM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e12033-e12033	2.2	
140	Prognostic value of stem cell quantification in stage II colon cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21104-e21104	2.2	
139	An unusual suspect: an uncommon human-specific synonymous coding variant within the UGT1A6 gene explains a GWAS signal and protects against bladder cancer. <i>Genome Biology</i> , 2011 , 12,	18.3	78
138	Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2011 , 22, 477-9	2.4	6
137	Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2011 , 22, 817-21	2.4	2
136	Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. <i>European Journal of Epidemiology</i> , 2011 , 26, 229-36	12.1	12
135	Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2011 , 30 Suppl 1, 19-26	9.6	35
134	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 75-82	3.5	2
133	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 162-78	3.6	21
132	Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. <i>Clinical and Translational Oncology</i> , 2011 , 13, 341-7	3.6	11
131	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). <i>Clinical and Translational Oncology</i> , 2011 , 13, 411-8	3.6	11
130	Socioeconomic status and exposure to disinfection by-products in drinking water in Spain. <i>Environmental Health</i> , 2011 , 10, 18	6	16
129	First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 77, 78-84	7	52
128	Urinary pH, cigarette smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2011 , 32, 843-7	4.6	28
127	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. <i>Human Molecular Genetics</i> , 2011 , 20, 4282-9	5.6	82

126	Porocarcinoma: clinical evolution. <i>Dermatologic Surgery</i> , 2010 , 36, 264-7	1.7	8
125	Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. <i>European Journal of Cancer Care</i> , 2010 , 19, 648-55	2.4	26
124	UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. <i>British Journal of Cancer</i> , 2010 , 103, 581-9	8.7	72
123	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010 , 42, 978-84	36.3	408
122	Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. <i>Environmental Health Perspectives</i> , 2010 , 118, 1545-50	8.4	162
121	Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. <i>Cancer Letters</i> , 2010 , 290, 192-203	9.9	47
120	Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. <i>Anti-Cancer Drugs</i> , 2010 , 21 Suppl 1, S3-11	2.4	83
119	Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. <i>American Journal of Human Genetics</i> , 2010 , 87, 129-38	11	100
118	Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2010 , 12, 142-7	3.6	21
117	Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). <i>Clinical and Translational Oncology</i> , 2010 , 12, 481-92	3.6	5
116	Occupational exposures and risk of pancreatic cancer. <i>European Journal of Epidemiology</i> , 2010 , 25, 721-30	12.1	24
115	Biallelic MYH germline mutations as cause of Muir-Torre syndrome. <i>Familial Cancer</i> , 2010 , 9, 151-4	3	12
114	Genetic susceptibility to distinct bladder cancer subphenotypes. <i>European Urology</i> , 2010 , 57, 283-92	10.2	52
113	A polymeric chip for micromanipulation and particle sorting by ultrasounds based on a multilayer configuration. <i>Sensors and Actuators B: Chemical</i> , 2010 , 144, 310-317	8.5	28
112	Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. <i>Annals of Oncology</i> , 2009 , 20, 251-7	10.3	12
111	Determinants of quality of interview and impact on risk estimates in a case-control study of bladder cancer. <i>American Journal of Epidemiology</i> , 2009 , 170, 237-43	3.8	8
110	Utility of p16 immunohistochemistry for the identification of Lynch syndrome. <i>Clinical Cancer Research</i> , 2009 , 15, 3156-62	12.9	15
109	The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study. <i>BMC Cancer</i> , 2009 , 9, 193	4.8	14

108	The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study. <i>BMC Cancer</i> , 2009 , 9, 406	4.8	12
107	TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. <i>International Journal of Cancer</i> , 2009 , 124, 608-13	7.5	41
106	Lifetime history of alcohol consumption and K-ras mutations in pancreatic ductal adenocarcinoma. <i>Environmental and Molecular Mutagenesis</i> , 2009 , 50, 421-30	3.2	9
105	Coffee consumption, genetic susceptibility and bladder cancer risk. <i>Cancer Causes and Control</i> , 2009 , 20, 121-7	2.8	32
104	Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study. <i>Cancer Causes and Control</i> , 2009 , 20, 591-9	2.8	9
103	Bladder cancer and reproductive factors among women in Spain. <i>Cancer Causes and Control</i> , 2009 , 20, 1907-13	2.8	13
102	Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. <i>Clinical and Translational Oncology</i> , 2009 , 11, 446-54	3.6	4
101	Recommendations on current approach to gastric cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 518-25	3.6	3
100	Adjuvant chemotherapy for stages II, III and IV of colon cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 526-33	3.6	26
99	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 134-44	7	42
98	Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1430-6	4	30
97	Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. <i>Lung Cancer</i> , 2009 , 63, 83-7	5.9	9
96	Micronuclei assessment in the urothelial cells of women using hair dyes and its modulation by genetic polymorphisms. <i>Cancer Letters</i> , 2008 , 263, 259-66	9.9	14
95	Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). <i>European Journal of Cancer</i> , 2008 , 44, 2204-11	7.5	34
94	Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. <i>Lancet Oncology</i> , 2008 , 9, 359-66	21.7	193
93	Capecitabine plus oxaliplatin for the treatment of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 161-74	3.5	9
92	Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. <i>Acta Oncologica</i> , 2008 , 47, 286-92	3.2	11
91	Air pollution and risk of urinary bladder cancer in a case-control study in Spain. <i>Occupational and Environmental Medicine</i> , 2008 , 65, 56-60	2.1	51

90	Occupation and bladder cancer in a hospital-based case-control study in Spain. <i>Occupational and Environmental Medicine</i> , 2008 , 65, 347-53	2.1	48
89	Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. <i>Carcinogenesis</i> , 2008 , 29, 1955-62	4.6	76
88	Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. <i>Clinical and Translational Oncology</i> , 2008 , 10, 241-5	3.6	2
87	Does increased urination frequency protect against bladder cancer?. <i>International Journal of Cancer</i> , 2008 , 123, 1644-8	7.5	25
86	Work in the textile industry in Spain and bladder cancer. <i>Occupational and Environmental Medicine</i> , 2008 , 65, 552-9	2.1	14
85	Adjuvant treatment of colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S42-6		30
84	Accomplishments in 2007 in the treatment of advanced colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S19-24		1
83	Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer. <i>Environmental Health Perspectives</i> , 2007 , 115, 1569-72	8.4	53
82	Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. <i>International Journal of Cancer</i> , 2007 , 120, 2452-8	7.5	53
81	Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. <i>Clinical Cancer Research</i> , 2007 , 13, 3545-51	12.9	164
80	Resolution of pleural effusion in a IgD multiple myeloma after chemotherapy based on liposomal doxorubicin. <i>Chinese-German Journal of Clinical Oncology</i> , 2007 , 6, 509-510		2
79	Genetic variation in the base excision repair pathway and bladder cancer risk. <i>Human Genetics</i> , 2007 , 121, 233-42	6.3	107
78	Panhypopituitarism as first manifestation of a lung cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 53-5	3.6	2
77	Guidelines for the detection and treatment of liver metastases of colorectal cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 723-30	3.6	7
76	Deposition-associated diseases related with a monoclonal compound. <i>Clinical and Translational Oncology</i> , 2007 , 9, 777-83	3.6	1
75	Bulky DNA adduct formation and risk of bladder cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 2155-9	4	10
74	Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. <i>Molecular Cancer Research</i> , 2007 , 5, 641-53	6.6	34
73	Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. <i>PLoS Genetics</i> , 2007 , 3, e29	6	109

72	Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. <i>Carcinogenesis</i> , 2007 , 28, 1788-93	4.6	83
71	Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1595-600	4	70
70	Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer. <i>Journal of Epidemiology and Community Health</i> , 2007 , 61, 641-9	5.1	22
69	Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4224-30	2.2	219
68	Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. <i>International Journal of Epidemiology</i> , 2007 , 36, 236-41	7.8	31
67	Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer. <i>Pancreas</i> , 2007 , 35, 135-41	2.6	22
66	Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. <i>European Journal of Cancer</i> , 2007 , 43, 1731-40	7.5	99
65	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. <i>European Journal of Cancer</i> , 2007 , 43, 2037-45	7.5	203
64	Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. <i>American Journal of Epidemiology</i> , 2007 , 165, 148-56	3.8	382
63	Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). <i>Clinical and Translational Oncology</i> , 2006 , 8, 98-102	3.6	5
62	Molecular biology of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2006 , 8, 306-12	3.6	6
61	Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1348-54	4	121
60	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006 , 17, 467-72	10.3	106
59	PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. <i>Cancer Research</i> , 2006 , 66, 7401-4	10.1	175
58	The p53 pathway and outcome among patients with T1G3 bladder tumors. <i>Clinical Cancer Research</i> , 2006 , 12, 6029-36	12.9	53
57	Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3664-71	2.2	256
56	Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 536-42	4	128
55	Assessment of lifetime exposure to trihalomethanes through different routes. <i>Occupational and Environmental Medicine</i> , 2006 , 63, 273-7	2.1	47

54	Anti-VEGF therapy: a new approach to colorectal cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1385-96	3.5	13
53	P53 IN BLADDER CANCER PROGNOSIS. RESULTS FROM A PROSPECTIVE MULTICENTRIC STUDY IN SPAIN. <i>European Urology Supplements</i> , 2006 , 5, 805	0.9	2
52	Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. <i>European Journal of Cancer</i> , 2006 , 42, 1448-54	7.5	42
51	Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1696-702	4	41
50	UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors. <i>Anti-Cancer Drugs</i> , 2006 , 17, 417-21	2.4	1
49	NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. <i>Lancet, The</i> , 2005 , 366, 649-59	40	483
48	Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2005 , 4, 384-9	3.8	7
47	Capecitabine as adjuvant treatment for stage III colon cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 2696-704	59.2	958
46	Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. <i>Histopathology</i> , 2005 , 46, 389-95	7.3	13
45	Adjuvant therapy of resected gastric cancer is necessary. <i>Seminars in Oncology</i> , 2005 , 32, S105-8	5.5	24
44	Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. <i>Clinical and Translational Oncology</i> , 2005 , 7, 189-97	3.6	179
43	Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005 , 16, 597-601	10.3	19
42	Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3545-51	2.2	85
41	Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1222-30	6.1	50
40	FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. <i>Clinical Cancer Research</i> , 2005 , 11, 5444-50	12.9	106
39	Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. <i>Annals of Oncology</i> , 2004 , 15, 559-67	10.3	5
38	Elderly colorectal cancer patients are under treated. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 8-13	1.6	3
37	Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2004 , 6, 175-83	4.9	25

36	Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. <i>Anti-Cancer Drugs</i> , 2004 , 15, 469-71	2.4	4
35	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. <i>Annals of Oncology</i> , 2003 , 14, 222-13	10.3	130
34	Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3207-13	2.2	159
33	Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. <i>European Urology</i> , 2003 , 43, 53-62	10.2	42
32	Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. <i>International Journal of Cancer</i> , 2003 , 107, 635-41	7.5	47
31	Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. <i>Lung Cancer</i> , 2003 , 39, 201-7	5.9	12
30	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. <i>Annals of Oncology</i> , 2003 , 14, 1549-54	10.3	7
29	Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2003 , 25, 639-43		5
28	Oxaliplatin: results in colorectal carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 44, 29-44	7	42
27	Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. <i>Journal of Epidemiology and Community Health</i> , 2002 , 56, 734-8	5.1	17
26	Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. <i>Carcinogenesis</i> , 2002 , 23, 101-6	4.6	40
25	Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. <i>Clinical Colorectal Cancer</i> , 2001 , 1, 43-6	3.8	2
24	Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1071-7	2.2	45
23	Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group. <i>European Journal of Epidemiology</i> , 2000 , 16, 533-41	12.1	31
22	Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group. <i>International Journal of Epidemiology</i> , 2000 , 29, 1004-13	7.8	30
21	Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda. <i>Journal of Epidemiology and Community Health</i> , 2000 , 54, 656-9	5.1	17
20	The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000 , 1502, 283-96	6.9	20
19	Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. <i>Lung Cancer</i> , 2000 , 28, 97-107	5.9	32

18	Cisplatin and vinorelbine combination chemotherapy in inoperable non small cell lung cancer (NSCLC) : a multicenter phase II trial 2000 , 2, 84-90		1
17	Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer 2000 , 2, 154-158		2
16	Risk of pancreatic cancer and occupational exposures in Spain. PANKRAS II Study Group. <i>Annals of Occupational Hygiene</i> , 2000 , 44, 391-403		14
15	Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. <i>Journal of Epidemiology and Community Health</i> , 1999 , 53, 702-9	5.1	50
14	Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. PANKRAS II Study Group. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 2469-77	4	23
13	Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. <i>Lancet, The</i> , 1999 , 354, 2125-9	40	146
12	Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 12-8	2.2	390
11	Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. <i>Annals of Oncology</i> , 1998 , 9, 727-31	10.3	78
10	Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 151-4	2.7	4
9	Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 1997 , 17, 261-9	5.9	15
8	Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Annals of Oncology</i> , 1996 , 7, 581-5	10.3	13
7	A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Cancer</i> , 1995 , 76, 559-63	6.4	21
6	Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.). <i>Annals of Oncology</i> , 1992 , 3, 861-3	10.3	11
5	A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992 , 15, 56-60	2.7	12
4	Detection of intracytoplasmic immunoglobulin by flow cytometry in B-cell malignancies. <i>Journal of Histochemistry and Cytochemistry</i> , 1989 , 37, 83-9	3.4	12
3	Detection of terminal deoxynucleotidyl transferase (TdT) by flow cytometry in leukemic disorders. <i>Journal of Histochemistry and Cytochemistry</i> , 1989 , 37, 509-13	3.4	14
2	Mild pancreatic damage in acute viral hepatitis. <i>Digestion</i> , 1989 , 42, 93-7	3.6	14
1	Hodgkin's disease after treatment of non-Hodgkin's lymphoma. <i>Cancer</i> , 1987 , 60, 887-96	6.4	15

